Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.4K citations

Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.

Masahiko Taniguchi, Toshirou Nishida, Seiichi Hirota et al. · PubMed · 1999 · 358 citations

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Teh‐Ying Chou, Chao‐Hua Chiu, Ling‐Hui Li et al. · Clinical Cancer Research · 2005 · 321 citations

KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas

Chin‐Chen Pan, Paul Chih‐Hsueh Chen, Hung Chiang · The Journal of Pathology · 2004 · 178 citations

Mutational status of EGFR and KIT in thymoma and thymic carcinoma

Kiyotaka Yoh, Yutaka Nishiwaki, Genichiro Ishii et al. · Lung Cancer · 2008 · 109 citations

Tumor Biology, Pathology, Thyroid Hormone +6